Albert Bourla was born on October 21, 1961, in Thessaloniki, Greece, to Sephardi Jewish parents who survived the Holocaust.
Albert Bourla was born on October 21, 1961, in Thessaloniki, Greece, to Sephardi Jewish parents who survived the Holocaust. ◦ He earned a doctorate in the biotechnology of reproduction at Aristotle University of Thessaloniki's Veterinary School in 1985. ◦ Bourla joined Pfizer in 1993 as a veterinarian and technical director for the animal health division in Greece. ◦ He became chief operating officer on January 1, 2018, was promoted to CEO effective January 1, 2019, succeeding his mentor Ian Read, and assumed the post of executive chairman in January 2020. ◦ In 2022, he was awarded the Genesis Prize for his vaccine leadership and directed the funds toward Holocaust education and the Holocaust Museum of Greece in Thessaloniki. ◦
Bourla told his team that "financial returns should not drive any decisions" regarding the vaccine, and he has stated that saving lives—as many and as soon as possible—would be the top priority. ◦ ◦ He holds that the only path to financial success for a pharmaceutical company is to create value for patients. ◦ He is a committed optimist, stating that nothing great on earth has been accomplished without an optimist behind it, while acknowledging that pessimists help avoid pitfalls by landing one in reality. ◦ He credits his mother for his outlook, noting she believed every obstacle is an opportunity to do something better and that nothing is impossible. ◦ He believes winners are differentiated from losers not because they never fall, but because they always stand up again. ◦ He maintains that people with opposing views should not be turned against, but rather educated and helped to understand. ◦
Bourla is willing to take significant risks when he believes the moral imperative is clear, such as manufacturing the COVID-19 vaccine before FDA approval and self-funding the effort to avoid letting financial returns alone drive the decision. ◦ ◦ He describes his approach as "higher risk, higher reward," while noting "I'm not suicidal." ◦ During the COVID-19 crisis, he adopted a posture of decisive action, stating, "There's nothing to decide. There's no option. We do it." ◦ He relentlessly pushes operational leaders, asking why more cannot be made sooner, and works to isolate scientists from financial concerns and excessive bureaucracy. ◦ He admits he was not ready to be the final line for decision-making, but overcame this by trusting his instinct and judgment. ◦ He accepts that "the buck stops here." ◦ He also critiques conservative goal-setting, saying, "Our problem is that we aim low and hit." ◦
Bourla operates with a dual-lens model of optimism and realism: he believes optimists provide the vision and that everyone follows an optimist, while pessimists land one to reality and help avoid pitfalls. ◦ His formula for leadership is to surround himself with a team that grounds him in reality while he remains the optimist. ◦ He sees resilience as the key differentiator between winners and losers in life. ◦ He inherited a mental model from his mother that every obstacle is an opportunity and nothing is impossible. ◦ He recognizes that teams will do ten times more than a leader thinks they will. ◦
Bourla holds a doctorate in the biotechnology of reproduction from a veterinary school and began his career as a veterinarian in Pfizer's animal health division. ◦ He led Pfizer's fast development of a COVID-19 vaccine in partnership with BioNTech. ◦ He has articulated ambitious goals in oncology, stating he thinks Pfizer should be able to cure some cancers while turning the remaining ones into chronic diseases. ◦ He views pharmaceutical success as fundamentally dependent on creating value for patients. ◦
Bourla reframes challenges in moral and human terms rather than purely technical or financial ones. ◦ During the COVID-19 vaccine push, he lined Pfizer offices with signs reading "Time is life" and asked leaders warning of delays to calculate the number of lives that would be lost during those periods. ◦ He observes that when people are asked to do things they perceive as difficult or impossible, their first instinct is to use all their brainpower to develop arguments about why it cannot be made. ◦ He communicates unwavering commitment to goals, telling his team, "That's it. We are going to get it. Don't worry." ◦ He publicly articulates ambitious visions, such as the belief that some cancers should be curable and the remaining ones will become chronic diseases. ◦ He emphasizes authenticity, stating it is important for a leader to be seen as they are and that it is very difficult to fake it. ◦ He advocates for educating those with opposing views rather than turning against them. ◦
Bourla simultaneously de-emphasizes financial returns as a primary driver and acknowledges operating on a "higher risk, higher reward" basis, while clarifying he is "not suicidal." ◦ ◦ He pushes his organization relentlessly for speed and volume, yet also claims to free scientists from excessive bureaucracy. ◦ He insists on optimism as the leadership stance while explicitly valuing pessimists for keeping him grounded in reality. ◦ He admits he was not ready to be the final decision-maker, yet accepted the role and now believes there is no option but to act decisively. ◦ ◦
Bourla values character above other factors and seeks people who care about what they do, take responsibility, and are good people generally. ◦ He advises surrounding an optimistic leader with a team that lands them to reality. ◦ He believes in educating those with opposing views rather than turning against them. ◦ He expects teams to exceed expectations, noting they will do ten times more than a leader thought they would. ◦ He responds to moral framing and direct challenges to calculate human costs when assessing operational delays. ◦